Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Core Insights - Palvella Therapeutics is advancing its QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with a New Drug Application (NDA) submission planned for the second half of 2026, potentially becoming the first FDA-approved therapy for this condition affecting over 30,000 patients in the U.S. [1][4] Research and Development Highlights - Positive topline results from the Phase 3 SELVA study for QTORIN™ rapamycin were reported, meeting the primary endpoint with a mean change of +2.13 (p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) [5] - 95% of trial participants aged 6 years and older showed improvement on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [5] - QTORIN™ rapamycin was well-tolerated, with no serious adverse events reported and systemic levels below 2ng/mL [5] - Initiation of Phase 3 trial for cutaneous venous malformations and Phase 2 trials for clinically significant angiokeratomas and disseminated superficial actinic porokeratosis are planned for the second half of 2026 [2][12] Financial Overview - As of December 31, 2025, the company reported pro forma cash of approximately $274 million, reflecting net proceeds from a February 2026 equity financing [2][17] - Research and development expenses for 2025 were $22.8 million, up from $8.2 million in 2024, primarily due to increased clinical development activities [17] - General and administrative expenses rose to $15.8 million in 2025 from $5.9 million in 2024, attributed to increased headcount and professional services [17] - The net loss attributable to common stockholders for 2025 was $41.7 million, or $3.71 per share, compared to a loss of $17.4 million, or $7.83 per share, in 2024 [17][20] Corporate Developments - The company successfully closed an oversubscribed public offering generating $230 million in gross proceeds, enhancing its financial position [4][12] - Palvella is focused on building a leading biopharmaceutical company addressing serious, rare skin diseases and vascular malformations with no FDA-approved therapies [4][14] - Recent leadership appointments aim to strengthen the company's market access and human resources capabilities [12]